Pharmaceutical manufacturers of Pravastatin

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

For more than 40 years, Apotex has been a reputable name in the Canadian pharmaceutical industry, offering patients increased availability to high-quality, cost-effective medications

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’ remarkable success in North America and European operations have helped us emerge as a global brand in the world’s largest pharmaceutical markets.

Founded in 1978, Biocon Limited is the largest biotechnology company in India and a leading company in Asia, focusing on biopharmaceuticals and research services. It is an integrated and innovation-driven enterprise that provides affordable solutions for chronic diseases globally. The company develops, manufactures, and offers a diverse portfolio of Small Molecules APIs & Formulations and Complex Biologics, including Novels and Biosimilars like MAbs, rh-insulin& Insulin Analogs. Among its notable products are the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG, and India's first biologic BioMAb-EGFR for head and neck cancer. Additionally, it has developed Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, introduced as Alzumab for psoriasis in India in 2013.

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology".

We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis seen in recent years, we anticipate the development of new biotechnology processes and products from fermentation, a technology which humankind has been utilizing since time immemorial.

Daiichi Sankyo is an international pharmaceutical organization with its corporate roots in Japan. We offer pioneering products and services in over 20 nations across the globe. Leveraging over a century of scientific knowledge, our company taps into a rich history of creativity and a strong lineup of promising new medications to aid patients. Through the exceptional expertise and dedication of our 15,000 staff members worldwide, we develop inventive novel and generic medications, as well as fresh approaches to drug discovery and distribution. We are driven by a dedication to innovation and a deep concern for patients worldwide who require our medications.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Concord Biotech Limited is a prominent vertically integrated, research and development-driven biotechnological powerhouse that produces Active Pharmaceutical Ingredients using fermentation and semi-synthetic methods, as well as Finished formulations. Established in 2000, Concord has evolved from a single-product enterprise to a wide-ranging solution provider, offering products across varied therapeutic segments. Concord is internationally recognized for its products and holds a strong presence in over 50 countries worldwide with effective distribution infrastructure in markets such as North America, Europe, Japan, Central & Latin America, Africa, Australia, and other regions.

CCSB has developed more than 30 bulk pharmaceutical products including Anti-Anxiety agent, Antidiabetics, Laxatives, Antifungals, Antihistamines, Antiseptics, Antiulcerants, Cardiovascular drugs, Skeletal, Muscle relaxants, Hypolipaemics, Antineoplastic, Antihyperlipedemia and Immunosuppresant. In 1984, CCSB was the first pharmaceutical manufacturer in Taiwan inspected and approved by FDA for cGMP compliance. CCSB has filed DMF's for 19 products with the FDA.

Livzon Group is a full-fledged pharmaceutical company that integrates the advancement and exploration, manufacturing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients (API), chemical medication, diagnostic reagents, and more. Recently, Livzon has shifted its strategic focus to research and development in antibody medications and vaccines, and has set up specialized laboratories for this purpose.

Livzon Group Fuzhou Fuxing Pharmaceutical Co Ltd (FFPC) was founded in 1979. Livzon Pharmaceutical Group Inc purchased FFPC in 2004, aiming to transform it into a top-notch API production center and R&D center. FFPC is a sizable pharmaceutical company with two facilities, Gutian Fuxing Pharmaceutical Co., Ltd and Fuqing Jiangyin site. FFPC has state-of-the-art machinery and advanced technology.

Chongqing Daxin Pharmaceutical Co., Ltd. (herein referred as Chongqing Daxin) was established in 1941. It is a core member of PKU HealthCare Industry，which has been praised as the Key High-tech Enterprise of the National Torch Program, Nationwide Key Enterprise in Chemical and Pharmaceutical Industry, one of the National Top 100 Pharmaceutical Enterprises and the Exportation brand leader enterprise supported by Chongqing government. After over 70 year's development, it has become a biotech oriented and comprehensive pharmaceutical company which covers areas of APIs and finished dosages.

Youngjin Pharm. Ind. Co.,Ltd. is involved in the manufacturing, provision, and dispersal of pharmaceutical goods. The corporation supplies antibiotics, CNS, cardiovascular (CV), endocrine system, respiratory, anti-inflammatory and pain-relieving medications, antihistamines, antifungal agents, comprehensive nutritional products, urinary system treatments, vitamins and supplements, cosmetics, and tonic beverages, among other items. Youngjin Pharm. Ind. Co.,Ltd. offers its range of products in tablet, capsule, dried syrup (oral solution), suspension, topical ointments, injectables, and infusions. This company was established in Seoul, South Korea in 1962.

Tianwei Group specializes in the cultivation and processing of non-genetically modified soybeans as well as organic soybeans. With over two decades of experience dating back to 1998, our primary cultivation sites boast the world's highest quality non-GMO soybeans and are situated in Heilongjiang and Jilin. Additionally, the group has expanded into the manufacturing and processing of various food additives such as sodium alginate, carrageenan, and transglutaminase. Our three processing facilities are located in Heilongjiang, Jilin, and Shandong.

Blue Treasure specializes in the exploration and advancement, production, and dissemination of APIs and Intermediates utilizing traditional fermentation methods. Our existing range of products encompasses Pravastatin Sodium (API) and Mycophenolic Acid (intermediate/starting material). Our facility has undergone evaluations and gained approval from China MPA, US FDA, TGA, Korean MFDS, and PMDA